サマリー

This report contains market size and forecasts of Therapeutic Peptide in China, including the following market information:
China Therapeutic Peptide Market Revenue, 2016-2021, 2022-2027, ($ millions)
China Therapeutic Peptide Market Sales, 2016-2021, 2022-2027, (K Units)
China top five Therapeutic Peptide companies in 2020 (%)
The global Therapeutic Peptide market size is expected to growth from US$ XX million in 2020 to US$ XX million by 2027; it is expected to grow at a CAGR of XX% during 2021-2027.
The China Therapeutic Peptide market was valued at US$ XX million in 2020 and is projected to reach US$ XX million by 2027, at a CAGR of XX% during the forecast period.
QYResearch has surveyed the Therapeutic Peptide manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
China Therapeutic Peptide Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (K Units)
China Therapeutic Peptide Market Segment Percentages, By Type, 2020 (%)
Oral
Injection
Other

China Therapeutic Peptide Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (K Units)
China Therapeutic Peptide Market Segment Percentages, By Application, 2020 (%)
Cancer
Metabolic Disorders
Central Nervous System
Other

Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Therapeutic Peptide revenues in China market, 2016-2021 (Estimated), ($ millions)
Key companies Therapeutic Peptide revenues share in China market, 2020 (%)
Key companies Therapeutic Peptide sales in China market, 2016-2021 (Estimated), (K Units)
Key companies Therapeutic Peptide sales share in China market, 2020 (%)
Further, the report presents profiles of competitors in the market, key players include:
AbbVie
AstraZeneca
Ipsen
Eli Lilly
Merck
Novo Nordisk
Novartis
Johnson and Johnson
Sanofi
Teva
Takeda

ページTOPに戻る

目次

1 Introduction to Research & Analysis Reports
1.1 Therapeutic Peptide Market Definition
1.2 Market Segments
1.2.1 Segment by Type
1.2.2 Segment by Application
1.3 China Therapeutic Peptide Market Overview
1.4 Methodology & Sources of Information
1.4.1 Research Methodology
1.4.2 Research Process
1.4.3 Base Year

2 China Therapeutic Peptide Overall Market Size
2.1 China Therapeutic Peptide Market Size: 2021 VS 2027
2.2 China Therapeutic Peptide Revenue, Prospects & Forecasts: 2016-2027
2.3 China Therapeutic Peptide Sales: 2016-2027

3 Company Landscape
3.1 Top Therapeutic Peptide Players in China Market
3.2 Top China Therapeutic Peptide Companies Ranked by Revenue
3.3 China Therapeutic Peptide Revenue by Companies
3.4 China Therapeutic Peptide Sales by Companies
3.5 China Therapeutic Peptide Price by Manufacturer (2016-2021)
3.6 Top 3 and Top 5 Therapeutic Peptide Companies in China Market, by Revenue in 2020
3.7 Manufacturers Therapeutic Peptide Product Type
3.8 Tier 1, Tier 2 and Tier 3 Therapeutic Peptide Players in China Market
3.8.1 List of Tier 1 Therapeutic Peptide Companies in China
3.8.2 List of Tier 2 and Tier 3 Therapeutic Peptide Companies in China

4 Sights by Type
4.1 Overview
4.1.1 By Type - China Therapeutic Peptide Market Size Markets, 2021 & 2027
4.1.2 Oral
4.1.3 Injection
4.1.4 Other
4.2 By Type - China Therapeutic Peptide Revenue & Forecasts
4.2.1 By Type - China Therapeutic Peptide Revenue, 2016-2021
4.2.2 By Type - China Therapeutic Peptide Revenue, 2022-2027
4.2.3 By Type - China Therapeutic Peptide Revenue Market Share, 2016-2027
4.3 By Type - China Therapeutic Peptide Sales & Forecasts
4.3.1 By Type - China Therapeutic Peptide Sales, 2016-2021
4.3.2 By Type - China Therapeutic Peptide Sales, 2022-2027
4.3.3 By Type - China Therapeutic Peptide Sales Market Share, 2016-2027
4.4 By Type - China Therapeutic Peptide Price (Manufacturers Selling Prices), 2016-2027

5 Sights by Application
5.1 Overview
5.1.1 By Application - China Therapeutic Peptide Market Size, 2021 & 2027
5.1.2 Cancer
5.1.3 Metabolic Disorders
5.1.4 Central Nervous System
5.1.5 Other
5.2 By Application - China Therapeutic Peptide Revenue & Forecasts
5.2.1 By Application - China Therapeutic Peptide Revenue, 2016-2021
5.2.2 By Application - China Therapeutic Peptide Revenue, 2022-2027
5.2.3 By Application - China Therapeutic Peptide Revenue Market Share, 2016-2027
5.3 By Application - China Therapeutic Peptide Sales & Forecasts
5.3.1 By Application - China Therapeutic Peptide Sales, 2016-2021
5.3.2 By Application - China Therapeutic Peptide Sales, 2022-2027
5.3.3 By Application - China Therapeutic Peptide Sales Market Share, 2016-2027
5.4 By Application - China Therapeutic Peptide Price (Manufacturers Selling Prices), 2016-2027

6 Manufacturers & Brands Profiles
6.1 AbbVie
6.1.1 AbbVie Corporation Information
6.1.2 AbbVie Overview
6.1.3 AbbVie Therapeutic Peptide Sales and Revenue in China Market (2016-2021)
6.1.4 AbbVie Therapeutic Peptide Product Description
6.1.5 AbbVie Recent Developments
6.2 AstraZeneca
6.2.1 AstraZeneca Corporation Information
6.2.2 AstraZeneca Overview
6.2.3 AstraZeneca Therapeutic Peptide Sales and Revenue in China Market (2016-2021)
6.2.4 AstraZeneca Therapeutic Peptide Product Description
6.2.5 AstraZeneca Recent Developments
6.3 Ipsen
6.3.1 Ipsen Corporation Information
6.3.2 Ipsen Overview
6.3.3 Ipsen Therapeutic Peptide Sales and Revenue in China Market (2016-2021)
6.3.4 Ipsen Therapeutic Peptide Product Description
6.3.5 Ipsen Recent Developments
6.4 Eli Lilly
6.4.1 Eli Lilly Corporation Information
6.4.2 Eli Lilly Overview
6.4.3 Eli Lilly Therapeutic Peptide Sales and Revenue in China Market (2016-2021)
6.4.4 Eli Lilly Therapeutic Peptide Product Description
6.4.5 Eli Lilly Recent Developments
6.5 Merck
6.5.1 Merck Corporation Information
6.5.2 Merck Overview
6.5.3 Merck Therapeutic Peptide Sales and Revenue in China Market (2016-2021)
6.5.4 Merck Therapeutic Peptide Product Description
6.5.5 Merck Recent Developments
6.6 Novo Nordisk
6.6.1 Novo Nordisk Corporation Information
6.6.2 Novo Nordisk Overview
6.6.3 Novo Nordisk Therapeutic Peptide Sales and Revenue in China Market (2016-2021)
6.6.4 Novo Nordisk Therapeutic Peptide Product Description
6.6.5 Novo Nordisk Recent Developments
6.7 Novartis
6.7.1 Novartis Corporation Information
6.7.2 Novartis Overview
6.7.3 Novartis Therapeutic Peptide Sales and Revenue in China Market (2016-2021)
6.7.4 Novartis Therapeutic Peptide Product Description
6.7.5 Novartis Recent Developments
6.8 Johnson and Johnson
6.8.1 Johnson and Johnson Corporation Information
6.8.2 Johnson and Johnson Overview
6.8.3 Johnson and Johnson Therapeutic Peptide Sales and Revenue in China Market (2016-2021)
6.8.4 Johnson and Johnson Therapeutic Peptide Product Description
6.8.5 Johnson and Johnson Recent Developments
6.9 Sanofi
6.9.1 Sanofi Corporation Information
6.9.2 Sanofi Overview
6.9.3 Sanofi Therapeutic Peptide Sales and Revenue in China Market (2016-2021)
6.9.4 Sanofi Therapeutic Peptide Product Description
6.9.5 Sanofi Recent Developments
6.10 Teva
6.10.1 Teva Corporation Information
6.10.2 Teva Overview
6.10.3 Teva Therapeutic Peptide Sales and Revenue in China Market (2016-2021)
6.10.4 Teva Therapeutic Peptide Product Description
6.10.5 Teva Recent Developments
6.11 Takeda
6.11.1 Takeda Corporation Information
6.11.2 Takeda Overview
6.11.3 Takeda Therapeutic Peptide Sales and Revenue in China Market (2016-2021)
6.11.4 Takeda Therapeutic Peptide Product Description
6.11.5 Takeda Recent Developments

7 China Therapeutic Peptide Production Capacity, Analysis
7.1 China Therapeutic Peptide Production Capacity, 2016-2027
7.2 Therapeutic Peptide Production Capacity of Key Manufacturers in China Market

8 Key Market Trends, Opportunity, Drivers and Restraints
8.1 Market Opportunities & Trends
8.2 Market Drivers
8.3 Market Restraints

9 Therapeutic Peptide Supply Chain Analysis
9.1 Therapeutic Peptide Industry Value Chain
9.2 Therapeutic Peptide Upstream Market
9.3 Therapeutic Peptide Downstream and Clients
9.4 Marketing Channels Analysis
9.4.1 Marketing Channels
9.4.2 Therapeutic Peptide Distributors and Sales Agents in China Market

10 Conclusion
11 Appendix
11.1 Note
11.2 Examples of Clients
11.3 Author Details
11.4 Disclaimer